Precision BioSciences Inc (NASDAQ:DTIL) – Stock analysts at William Blair dropped their Q1 2020 EPS estimates for shares of Precision BioSciences in a research note issued on Tuesday, March 10th. William Blair analyst R. Prasad now forecasts that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.42). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Precision BioSciences’ Q2 2020 earnings at ($0.47) EPS, Q3 2020 earnings at ($0.51) EPS, Q4 2020 earnings at ($0.51) EPS, FY2020 earnings at ($1.93) EPS and FY2021 earnings at ($2.00) EPS.
Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.15. The firm had revenue of $6.52 million for the quarter, compared to analyst estimates of $9.56 million. Precision BioSciences had a negative return on equity of 66.96% and a negative net margin of 417.65%.
Other equities research analysts have also issued reports about the company. ValuEngine upgraded Precision BioSciences from a “hold” rating to a “buy” rating in a research report on Wednesday, March 4th. Stifel Nicolaus assumed coverage on Precision BioSciences in a research report on Wednesday, March 4th. They issued a “buy” rating and a $21.00 price objective on the stock. HC Wainwright cut their price objective on Precision BioSciences from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Zacks Investment Research cut Precision BioSciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $21.29.
Shares of DTIL stock opened at $6.18 on Thursday. The firm has a market cap of $287.84 million and a P/E ratio of -1.96. Precision BioSciences has a fifty-two week low of $5.24 and a fifty-two week high of $23.67. The business’s 50 day moving average price is $8.16 and its 200-day moving average price is $10.02.
In other news, insider Christopher Heery bought 2,485 shares of the stock in a transaction dated Thursday, December 19th. The stock was bought at an average price of $12.08 per share, for a total transaction of $30,018.80. Following the purchase, the insider now directly owns 250 shares in the company, valued at approximately $3,020. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC lifted its stake in shares of Precision BioSciences by 993.9% in the 4th quarter. Nuveen Asset Management LLC now owns 148,595 shares of the company’s stock valued at $2,064,000 after purchasing an additional 135,011 shares during the period. Adams Chetwood Wealth Management LLC purchased a new position in Precision BioSciences during the fourth quarter valued at $9,978,000. Geode Capital Management LLC raised its stake in Precision BioSciences by 100.9% during the fourth quarter. Geode Capital Management LLC now owns 283,255 shares of the company’s stock valued at $3,934,000 after buying an additional 142,238 shares during the last quarter. Capital World Investors raised its stake in Precision BioSciences by 549.9% during the fourth quarter. Capital World Investors now owns 4,062,000 shares of the company’s stock valued at $56,421,000 after buying an additional 3,437,000 shares during the last quarter. Finally, Algert Global LLC purchased a new position in Precision BioSciences during the fourth quarter valued at $380,000. Institutional investors own 55.01% of the company’s stock.
Precision BioSciences Company Profile
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.